World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
102
Citations
66042
World Ranking
656
National Ranking
383

Medicine

D-Index
104
Citations
66484
World Ranking
6895
National Ranking
3637

Robert T. Schooley publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Robert T. Schooley sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 401 publications — 81st percentile

81% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Robert T. Schooley D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Robert T. Schooley sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 102 D-Index — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Robert T. Schooley is affiliated with the University of California, San Diego in the United States. Their research primarily focuses on medicine, with specific contributions to immunology and microbiology. The scientist's work spans several subfields including infectious diseases, virology, public health, environmental and occupational health, epidemiology, and parasitology.

Their research topics emphasize HIV/AIDS drug development and treatment, HIV research and treatment, and HIV/AIDS research and interventions. Additional areas of study include malaria research and control, HIV-related health complications and treatments, antibiotic resistance in bacteria, and antibiotics pharmacokinetics and efficacy.

Recent publications by Robert T. Schooley cover a range of topics pertinent to infectious diseases and HIV treatment. These include:

  • Antiretroviral Treatment of Adult HIV Infection 2008 Recommendations of the International AIDS Society-USA Panel, 2020, UNC Libraries
  • Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group, 2023, Clinical Infectious Diseases
  • Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial, 2022, Journal of the International AIDS Society
  • Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria, 2021, AIDS
  • Design and Implementation of Postgraduate Programs in Health in a Resource-Limited Setting in Mozambique (The Lúrio University), 2021, Advances in Medical Education and Practice

The scientist frequently collaborates with other researchers. Notable coauthors include Evelyn Hogg, John W. Mellors, Ann C. Collier, Emília Virgínia Noormahomed, and Constance A. Benson.

Robert T. Schooley has contributed to multiple publications in journals and venues such as UNC Libraries, Clinical Infectious Diseases, Journal of the International AIDS Society, AIDS, and Advances in Medical Education and Practice.

Best Publications

  • Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework*

    Arthur J. Atkinson;Wayne A. Colburn;Victor G. DeGruttola;David L. DeMets

  • The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo-controlled trial.

    Margaret A Fischl;D. D. Richman;M. H. Grieco;M. S. Gottlieb

  • Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents

    A. S. Fauci;J. G. Bartlett;E. P. Goosby;M. D. Smith

  • Chronic Fatigue Syndrome: A Working Case Definition

    Gary P. Holmes;Jonathan E. Kaplan;Nelson M. Gantz;Anthony L. Komaroff

  • Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel

    Huldrych F Gunthard;Judith A Aberg;Joseph J Eron;Jennifer Frances Hoy

  • A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter

    Scott M. Hammer;David A. Katzenstein;Michael D. Hughes;Holly Gundacker

  • Antiretroviral Therapy in Adults: Updated Recommendations of the International AIDS Society–USA Panel

    Charles C. J. Carpenter;David A. Cooper;Margaret A. Fischl;Jose M. Gatell

  • Isolation of HTLV-III from Cerebrospinal Fluid and Neural Tissues of Patients with Neurologic Syndromes Related to the Acquired Immunodeficiency Syndrome

    D D Ho;T R Rota;R T Schooley;J C Kaplan

  • Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus

    Rebekah M. Dedrick;Carlos A. Guerrero-Bustamante;Rebecca A. Garlena;Daniel A. Russell

  • Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection

    Robert T. Schooley;Biswajit Biswas;Jason J. Gill;Adriana Hernandez-Morales

  • Treatment for adult HIV infection : 2006 recommendations of the international AIDS society-USA panel

    Scott M. Hammer;Michael S. Saag;Mauro Schechter;Julio S. G. Montaner

  • Vidarabine versus Acyclovir Therapy in Herpes Simplex Encephalitis

    Richard J. Whitley;Charles A. Alford;Martin S. Hirsch;Robert T. Schooley

  • HIV-specific cytotoxic T lymphocytes in seropositive individuals.

    Bruce D. Walker;Sekhar Chakrabarti;Bernard Moss;Timothy J. Paradis

  • Antiretroviral Therapy for HIV Infection in 1997: Updated Recommendations of the International AIDS Society—USA Panel

    Charles C. J. Carpenter;Margaret A. Fischl;Scott M. Hammer;Martin S. Hirsch

  • Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel

    Patrick G. Yeni;Scott M. Hammer;Charles C. J. Carpenter;David A. Cooper

  • Antiretroviral Therapy for HIV Infection in 1998: Updated Recommendations of the International AIDS Society–USA Panel

    Charles C. J. Carpenter;Margaret A. Fischl;Scott M. Hammer;Martin S. Hirsch

  • Reducing transmission of SARS-CoV-2.

    Kimberly A. Prather;Chia C. Wang;Robert T. Schooley

  • Ten scientific reasons in support of airborne transmission of SARS-CoV-2.

    Trisha Greenhalgh;Jose L Jimenez;Kimberly A Prather;Zeynep Tufekci

  • Antiretroviral Treatment of Adult HIV Infection

    Scott M. Hammer;Joseph J. Eron;Peter Reiss;Robert T. Schooley

  • Phage therapy: From biological mechanisms to future directions

    Unknown

  • Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel

    Charles C. J. Carpenter;Margaret A. Fischl;Scott M. Hammer;Martin S. Hirsch

  • Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

    Patrick G. Yeni;Scott M. Hammer;Martin S. Hirsch;Michael S. Saag

  • HIV infection is blocked in vitro by recombinant soluble CD4

    Richard A. Fisher;Jeanne M. Bertonis;Werner Meier;Victoria A. Johnson

  • HTLV-III in the semen and blood of a healthy homosexual man.

    David D. Ho;Robert T. Schooley;Teresa R. Rota;Joan C. Kaplan

  • Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins.

    D D Ho;M G Sarngadharan;M S Hirsch;R T Schooley

Frequent Co-Authors

Martin S. Hirsch
Martin S. Hirsch Harvard Medical School
Constance A. Benson
Constance A. Benson University of California, San Diego
Douglas D. Richman
Douglas D. Richman University of California, San Diego
Daniel R. Kuritzkes
Daniel R. Kuritzkes Brigham and Women's Hospital
Paul A. Volberding
Paul A. Volberding University of California, San Francisco
Margaret A. Fischl
Margaret A. Fischl University of Miami
Michael S. Saag
Michael S. Saag University of Alabama at Birmingham
Bruce D. Walker
Bruce D. Walker Harvard University
Scott M. Hammer
Scott M. Hammer Columbia University
Robert H. Rubin
Robert H. Rubin Brigham and Women's Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related healthcare degrees online can open diverse career opportunities. Nurse Practitioner programs, especially those focused on psychiatric and mental health nursing, often complement immunological studies by enhancing clinical skills and patient care knowledge. If you are considering such paths, exploring which nurse practitioner program is easiest can help you find a program that balances flexibility and depth while fitting your lifestyle.

Clinical placement is a critical factor in nursing education success. Choosing online pmhnp programs with clinical placement ensures hands-on experience, helping bridge theory and practice efficiently. Additionally, budget considerations come into play, making it essential to know about affordable pmhnp programs that maintain quality education without overwhelming financial burdens.

Ultimately, evaluating financial outcomes is important. Understanding how much a DNP makes by state can guide your decision-making process by providing insight into potential returns on investment after completing advanced nursing or immunology-related degrees.

Best Scientists Citing Robert T. Schooley

Trending Scientists

Recently Published Articles